Era Regenerative Medicine Ltd - 04 Jun 2025 Form 4 Insider Report for REED'S, INC. (REED)

Reporting relationship: 10%+ Owner
Issuer ticker: REED
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2025, 16:36:43 UTC
Prior SEC filing: 28 Feb 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Dai Siqi, sole director of Era Regenerative Medicine Ltd.

Key filing fact

Era Regenerative Medicine Ltd filed Form 4 for REED'S, INC. (REED) on 11 Jun 2025.

Key facts

This page summarizes Era Regenerative Medicine Ltd's Form 4 filing for REED'S, INC. (REED).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jun 2025, 16:36.

Change

Previous filing in this sequence was filed on 28 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002053961 Primary reporting owner

Era Regenerative Medicine Ltd

Relationship: 10%+ Owner
Address: 501 MERRITT 7 CORPORATE PARK PH, NORWALK
Signature: By: /s/ Dai Siqi, sole director of Era Regenerative Medicine Ltd.
Signature date: 10 Jun 2025

CIK 0001979652

D&D Source of Life Holding Ltd.

Relationship: 10%+ Owner
Address: GENESIS BUILDING, 5TH FLOOR,, GENESIS CLOSE, GEORGE TOWN,PO BOX 446, GRAND CAYMAN
Signature: By: /s/ Dai Siqi, on behalf of Era Regenerative Medicine Ltd.
Signature date: 10 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REED transaction

Common Stock

Purchase

Transaction value
Shares: +1,075,269
Change %: +4%
Price
Shares after: 28,214,789
Date: 04 Jun 2025
Ownership: See footnote
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

D&D Source of Life Holding Ltd. ("D&D"), participated in the Registrant's PIPE transaction.

Footnote F2

The purchase price per share was $0.93.

Footnote F3

Includes 232,108 shares of common stock issuable upon exercise of currently exercisable warrants.

Footnote F4

Era Regenerative Medicine Ltd.("ERM") holds all the shares in D&D. Dai Siqi, currently the sole director of ERM, has sole voting and dispositive power over the securities of the Registrant held directly by D&D.

SEC remarks

Dai Siqi disclaims beneficial ownership in the securities of the Registrant except for his pecuniary interest therein as sole director of ERM.